RLYB Profile
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering, developing, and delivering innovative therapies aimed at treating severe and rare diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies that can significantly improve patient outcomes for conditions with high unmet medical needs. Rallybio’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase I clinical trials. This therapy is designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can cause low platelet counts in newborns and lead to severe health complications.
In addition to RLYB212, Rallybio is advancing several other promising candidates. RLYB211, a polyclonal anti-HPA-1a antibody, is in a Phase 1/2 clinical trial for the same indication, offering a potential alternative therapeutic approach for preventing FNAIT. Another key development is RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule currently in preclinical development. This candidate aims to address complement-mediated ophthalmic diseases, representing a novel approach to treating conditions related to complement system dysregulation.
Rallybio is also developing RLYB116, an innovative subcutaneously administered inhibitor of C5, targeting conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (GMG). This therapy is designed to provide a new treatment option for patients with these serious and challenging diseases. Rallybio’s strategic collaborations include a partnership with Exscientia, focusing on the development of small molecule therapeutics tailored for rare diseases. This collaboration highlights Rallybio’s commitment to leveraging advanced technologies and expertise to address niche yet critical therapeutic areas.
Founded in 2018, Rallybio has rapidly established itself as a key player in the biotechnology sector, driven by its mission to bring forward transformative therapies for underserved patient populations. The company’s robust pipeline and strategic alliances reflect its dedication to innovation and its goal of improving the lives of patients facing rare and severe health conditions.
|
